H Rosén1, L Rosengren, J Herlitz, C Blomstrand. 1. Institute of Clinical Neuroscience, Department of Neurology, Sahlgrens University Hospital, University of Göteborg, Sweden. hans.rosen@neuro.gu.se
Abstract
BACKGROUND AND PURPOSE: Patients resuscitated from cardiac arrest have a high early mortality rate. Prognostic evaluation based on clinical observations is uncertain and would benefit from the use of biochemical markers of hypoxic brain damage. The astroglial protein S-100 is an established biochemical marker of central nervous system injury. The purpose of the present study was to validate the use of serum determinations of S-100 with regard to outcome after cardiac arrest. METHODS: Levels of serum S-100 were measured with a radioimmunoassay in 41 patients the first 3 days after out-of-hospital cardiac arrest. The main outcome variable was fatal outcome within 14 days. RESULTS: S-100 levels were increased after cardiac arrest compared with controls with the highest levels observed the first day. S-100 levels day 1 and 2 correlated to the degree of coma as well as to the time of anoxia. Seventeen patients died within 14 days after the cardiac arrest. The deceased patients had increased S-100 levels on days 1 through 3 compared with survivors. All patients (100%) with an S-100 level of > or =0.2 on day 2 after the cardiac arrest died within 14 days, and 89% of the patients with levels below this limit value survived (positive and negative predictive values). The corresponding predictive values on day 1 were 71% and 85%, respectively. CONCLUSIONS: The present study shows that hypoxic brain damage after cardiac arrest can be estimated by measurement of serum S-100 concentrations. The method can be used in early prognostic evaluation of short-term outcome after cardiac arrest.
BACKGROUND AND PURPOSE:Patients resuscitated from cardiac arrest have a high early mortality rate. Prognostic evaluation based on clinical observations is uncertain and would benefit from the use of biochemical markers of hypoxic brain damage. The astroglial protein S-100 is an established biochemical marker of central nervous system injury. The purpose of the present study was to validate the use of serum determinations of S-100 with regard to outcome after cardiac arrest. METHODS: Levels of serum S-100 were measured with a radioimmunoassay in 41 patients the first 3 days after out-of-hospital cardiac arrest. The main outcome variable was fatal outcome within 14 days. RESULTS:S-100 levels were increased after cardiac arrest compared with controls with the highest levels observed the first day. S-100 levels day 1 and 2 correlated to the degree of coma as well as to the time of anoxia. Seventeen patients died within 14 days after the cardiac arrest. The deceased patients had increased S-100 levels on days 1 through 3 compared with survivors. All patients (100%) with an S-100 level of > or =0.2 on day 2 after the cardiac arrest died within 14 days, and 89% of the patients with levels below this limit value survived (positive and negative predictive values). The corresponding predictive values on day 1 were 71% and 85%, respectively. CONCLUSIONS: The present study shows that hypoxic brain damage after cardiac arrest can be estimated by measurement of serum S-100 concentrations. The method can be used in early prognostic evaluation of short-term outcome after cardiac arrest.
Authors: Elisabeth Paus; Mads Haugland Haugen; Kari Hauge Olsen; Kjersti Flatmark; Gunhild Mari Maelandsmo; Olle Nilsson; Eva Röijer; Maria Lundin; Christian Fermér; Maria Samsonova; Yuri Lebedin; Torgny Stigbrand Journal: Tumour Biol Date: 2010-07-24
Authors: Andrew Laflam; Brijen Joshi; Kenneth Brady; Gayane Yenokyan; Charles Brown; Allen Everett; Ola Selnes; Edward McFarland; Charles W Hogue Journal: Anesth Analg Date: 2015-01 Impact factor: 5.108
Authors: Robert Siman; Victoria L Roberts; Elizabeth McNeil; Antony Dang; Joseph E Bavaria; Sindhu Ramchandren; Michael McGarvey Journal: Brain Res Date: 2008-04-01 Impact factor: 3.252
Authors: J P Nolan; C D Deakin; J Soar; B W Böttiger; G Smith; M Baubin; B Dirks; V Wenzel Journal: Notf Rett Med Date: 2006-02-01 Impact factor: 0.826